CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) was the target of a large increase in short interest in the month of July. As of July 31st, there was short interest totalling 6,840,000 shares, an increase of 16.9% from the July 15th total of 5,850,000 shares. Approximately 16.8% of the shares of the company are short sold. Based on an average daily trading volume, of 653,700 shares, the short-interest ratio is presently 10.5 days.
CG Oncology Price Performance
Shares of CGON stock traded down $0.18 during mid-day trading on Friday, reaching $34.22. The stock had a trading volume of 468,517 shares, compared to its average volume of 647,165. CG Oncology has a one year low of $25.77 and a one year high of $50.23. The firm’s 50 day simple moving average is $33.28 and its 200 day simple moving average is $36.37.
CG Oncology (NASDAQ:CGON – Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.14. The firm had revenue of $0.11 million during the quarter. As a group, equities analysts expect that CG Oncology will post -1.64 EPS for the current year.
Wall Street Analysts Forecast Growth
Read Our Latest Stock Analysis on CGON
Institutional Trading of CG Oncology
Several institutional investors have recently made changes to their positions in the business. Decheng Capital LLC bought a new position in CG Oncology during the first quarter worth about $239,642,000. Vanguard Group Inc. acquired a new position in shares of CG Oncology in the 1st quarter worth approximately $97,678,000. BVF Inc. IL bought a new position in shares of CG Oncology during the 1st quarter worth approximately $82,716,000. Yu Fan acquired a new stake in CG Oncology in the 2nd quarter valued at $49,828,000. Finally, Janus Henderson Group PLC bought a new stake in CG Oncology in the first quarter valued at $66,757,000. 26.56% of the stock is currently owned by institutional investors and hedge funds.
CG Oncology Company Profile
CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.
See Also
- Five stocks we like better than CG Oncology
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- This Small Cap Wealth Management Stock Could Provide Big Returns
- What Investors Need to Know to Beat the Market
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- What Are Growth Stocks and Investing in Them
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.